Giving Voice to Patients through Data

Casimir Trials is a contract research organization that is seeking to bring patient and caregiver perspective into the clinical trials process. It’s working with drug developers to create endpoints and measures that can provide rigorous and quantifiable means of demonstrating whether an experimental therapy provides meaningful improvements to a patient’s quality of life. We spoke to Christine McSherry, co-founder and CEO of Casimir Trials, about the challenges of developing patient-centric outcome measures, how technology is allowing for the capture of real-world evidence, and how Casimir began with a challenge from the FDA’s Center for Drug Evaluation and Research Director Janet Woodcock to a mother and patient advocate concerned over the use of endpoints that could obscure the value of needed drugs to rare disease patients.

Learn more about this and other rare disease innovations in the Global Genes report, NEXT: Imagining the Future of Rare Disease.